Managing risks of neoplasia in inflammatory bowel disease

Current Gastroenterology Reports

Volumn 14, Issue 2, 2012, Pages 174-180

  Velayos, Fernando ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 aminosalicylic acid; Anti TNF; Cervical cancer; Cervical dysplasia; Colorectal cancer; Lymphoma; Non melanoma skin cancer; Small bowel adenocarcinoma; Thiopruine

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; CORTICOSTEROID; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; SUNSCREEN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; URSODEOXYCHOLIC ACID; WART VIRUS VACCINE;

ARTICLE; CANCER RISK; CANCER SCREENING; CHROMOENDOSCOPY; COLON ADENOMA; COLON BIOPSY; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL CARCINOMA; CROHN DISEASE; DISEASE ASSOCIATION; DRUG MEGADOSE; ENTERITIS; HUMAN; IMMUNE DEFICIENCY; IONIZING RADIATION; LYMPHOMA; MEDICAL LITERATURE; NARROW BAND IMAGING; NON MELANOMA SKIN CANCER; PAPANICOLAOU TEST; PATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; PRESCRIPTION; PROTECTIVE CLOTHING; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SMALL INTESTINE CARCINOMA; SUN EXPOSURE; ULCERATIVE COLITIS; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; WART VIRUS;

HUMANS; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; RISK FACTORS;

EID: 84861092341     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0247-7     Document Type: Article

References (53)

1. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141 (5):1621-8. e1621-1625.
2. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8(3):268-74.
3. Mellemkjaer L, Olsen JH, Frisch M, Johansen C, Gridley G, McLaughlin JK. Cancer in patients with ulcerative colitis. Int J Cancer. 1995;60(3):330-3.
4. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991;67 (7):2015-9.
5. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. Jul 30 2011.
6. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141(5):1612-20.
7. Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. preventive. Rockville (MD); 2009.
8. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006;12(38):6167-71. (Pubitemid 44688166)
9. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631-6. (Pubitemid 351405963)
10. Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case- control study. Gastroenterology. 2009;136(2):451-8.
11. Lees CW, Critchley J, Chee N, et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis. 2009;15(11):1621-9.
12. Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(5):598-605.
13. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343 (8908):1249-52. (Pubitemid 24158045)
14. Nguyen GC, Frick KD, Dassopoulos T. Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointest Endosc. 2009;69(7):1299-310.
15. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. May 28 2010;59(20):630-32.
16. Shaukat A, Virnig DJ, Howard D, Sitaraman SV, Liff JM, Lederle FA. Crohn's disease and small bowel adenocarcinoma: a population-based case-control study. Cancer Epidemiol Biomark Prev. 2011;20(6):1120-3.
17. Jess T, Loftus Jr. EV, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006;130 (4):1039-46.
18. Palascak-Juif V, Bouvier AM, Cosnes J, et al. Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis. 2005;11 (9):828-32. (Pubitemid 41368271)
19. Piton G, Cosnes J, Monnet E, et al. Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study. Am J Gastroenterol. 2008;103(7):1730-6.
20. Soyer P, Hristova L, Boudghene F, et al. Small bowel adenocarcinoma in Crohn disease: CT-enterography features with pathological correlation. Abdom Imaging. Jun 14 2011.
21. Solem CA, Harmsen WS, Zinsmeister AR, Loftus Jr. EV. Small intestinal adenocarcinoma in Crohn's disease: a case-control study. Inflamm Bowel Dis. 2004;10(1):32-5. (Pubitemid 38072443)
22. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451-9. (Pubitemid 38182302)
23. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal cancer in Crohn's disease: a metaanalysis of population-based cohort studies. Am J Gastroenterol. 2005;100(12):2724-9.
24. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006;23(8):1097-104. (Pubitemid 43779348)
25. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323(18):1228-33. (Pubitemid 20366527)
26. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4): 526-35. (Pubitemid 32234798)
27. Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120(6):1356-62. (Pubitemid 32322309)
28. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56(1):48-54. (Pubitemid 41115048)
29. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53(12):1813-6. (Pubitemid 39556902)
30. Velayos FS, Loftus Jr. EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130(7):1941-9. (Pubitemid 43816957)
31. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746-74. 774 e741-744; quiz e712-743.
32. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18 Suppl 2:10-4. (Pubitemid 37174711)
33. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100(6):1345-53. (Pubitemid 40904360)
34. Siegel CA, Sands BE. Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis. 2006;12 (6):491-6.
35. Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol. 2005;100(6):1354-6. (Pubitemid 40904361)
36. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99(7): 1371-85. (Pubitemid 39062279)
37. Davila RE, Rajan E, Baron TH, et al. ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc. 2006;63 (4):546-57.
38. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666-89.
39. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124(2):544-60. (Pubitemid 36169269)
40. Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(3):314-21. (Pubitemid 40439686)
41. Rutter MD, Saunders BP, Wilkinson KH, Kamm MA, Williams CB, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60(3):334-9. (Pubitemid 39164238)
42. Marion JF, Waye JD, Present DH, et al. Chromoendoscopytargeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103 (9):2342-9.
43. Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB, Talbot IC. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004;53(2):256-60. (Pubitemid 38125515)
44. Dekker E, van den Broek FJ, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy. 2007;39(3):216-21. (Pubitemid 46510792)
45. Beaugerie L, Brousse N, Bouvier AM, et al. Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD): interim results of the CESAME cohort. Gastroenterology. 2008;134(A):116-7.
46. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121(5):1080-7. (Pubitemid 33022087)
47. Loftus Jr. EV, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95(9):2308-12.
48. Mir-Madjlessi SH, Farmer RG, Easley KA, Beck GJ. Colorectal and extracolonic malignancy in ulcerative colitis. Cancer. 1986;58 (7):1569-74. (Pubitemid 16016846)
49. NCI. 2011; http://seer.cancer.gov/statfacts/html/lymph.html.
50. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121-5. (Pubitemid 41025906)
51. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617-25.
52. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874-81.
53. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36-41. e31.